Endocrine and Targeted Therapy for Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer—Capivasertib-Fulvestrant: ASCO Rapid Recommendation Update
Journal of Clinical Oncology · 20.04.2024 · 42 (12) · 1450-1453
DOI: 10.1200/jco.24.00248 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Clinical Oncology, erschienen am 20.04.2024. Verfasst von Harold J Burstein und 6 weiteren Autor:innen. Beteiligte Einrichtung: Dana Farber Cancer Institute, Boston, MA. Hauptthemen laut MEDLINE: Breast Neoplasms, Antineoplastic Combined Chemotherapy Protocols. Die Arbeit wurde bisher 74-mal zitiert (Crossref) und nennt 6 Literaturangaben.
Abstract (Originalsprache)
ASCO Rapid Recommendation Updates highlight revisions to select ASCO guideline recommendations as a response to the emergence of new and practice-changing data. The rapid updates are supported by an evidence review and follow the guideline development processes outlined in the ASCO Guideline Methodology Manual. The goal of these articles is to disseminate updated recommendations, in a timely manner, to better inform health practitioners and the public on the best available cancer care options. Guidelines and updates are not intended to substitute for independent professional judgment of the treating provider and do not account for individual variation among patients. See appendix for disclaimers and other important information ( Appendix 1 and Appendix 2 , online only).
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Dana Farber Cancer Institute, Boston, MA.
- University of Pennsylvania, Philadelphia, PA.
- University of Sussex, Brighton, United Kingdom.
- American Society of Clinical Oncology, Alexandria, VA.
- University of Michigan, Ann Arbor, MI.
ORCID-Profile: Harold J Burstein, Angela DeMichele, Mark R Somerfield, N Lynn Henry
Zitieren
APA
Burstein, H. J., DeMichele, A., Fallowfield, L., Somerfield, M. R., Henry, N. L., Biomarker Testing and Endocrine and Targeted Therapy in Metastatic Breast Cancer Expert Panels, & Biomarker Testing and Endocrine and Targeted Therapy in Metastatic Breast Cancer Expert Panels for the Endocrine and Targeted Therapy in Metastatic Breast Canc… (2024). Endocrine and Targeted Therapy for Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer—Capivasertib-Fulvestrant: ASCO Rapid Recommendation Update. Journal of Clinical Oncology, 42(12), 1450-1453. https://doi.org/10.1200/jco.24.00248
Vancouver
Burstein HJ, DeMichele A, Fallowfield L, Somerfield MR, Henry NL, Biomarker Testing and Endocrine and Targeted Therapy in Metastatic Breast Cancer Expert Panels, et al. Endocrine and Targeted Therapy for Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer—Capivasertib-Fulvestrant: ASCO Rapid Recommendation Update. Journal of Clinical Oncology. 2024;42(12):1450-1453. doi:10.1200/jco.24.00248
BibTeX
@article{Burstein2024,
author = {Burstein, Harold J and DeMichele, Angela and Fallowfield, Lesley and Somerfield, Mark R and Henry, N Lynn and Biomarker Testing and Endocrine and Targeted Therapy in Metastatic Breast Cancer Expert Panels, Biomarker Testing and Endocrine and Targeted Therapy in Metastatic Breast Cancer Expert Panels and Biomarker Testing and Endocrine and Targeted Therapy in Metastatic Breast Cancer Expert Panels for the Endocrine and Targeted Therapy in Metastatic Breast Canc…, Biomarker Testing and Endocrine and Targeted Therapy in Metastatic Breast Cancer Expert Panels for the Endocrine and Targeted Therapy in Metastatic Breast Canc…},
title = {Endocrine and Targeted Therapy for Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer—Capivasertib-Fulvestrant: ASCO Rapid Recommendation Update},
journal = {Journal of Clinical Oncology},
year = {2024},
volume = {42},
number = {12},
pages = {1450--1453},
doi = {10.1200/jco.24.00248}
}
EUVIMED